Roche recall
This article was originally published in The Gray Sheet
Executive Summary
Cobas Taqman and Taqman 48 analyzer Class I recall is ongoing, after the discovery that some analyzers have an "improperly seated fiber optic cable," which could falsely elevate patient hepatitis B and C virus test results. Because physicians stop or change treatment upon finding elevated test results - which show patients failing to respond to treatment - disease progression or death could result in some cases. Roche is considering redesigning the optic cable, and says its field service engineers have inspected 100 analyzers for correct cable seating. The Taqman action is a further example of an increased number of Class I recalls compared with prior years (1"The Gray Sheet" July 19, 2004, p. 16)...
You may also be interested in...
Zeiss Visulink Reflects Rise In Device Class I Recall Notifications
Carl Zeiss Meditec's Class I voluntary recall is part of a recent uptick in FDA announcements related to the most serious type of device recalls
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.